Abstract:BackgroundAlzheimer’s disease (AD) causes progressive loss of memory and cognition, exacerbated by APOE4, the greatest genetic risk factor for AD. One proposed mechanism for apolipoprotein E (apoE) effects on cognition is via NMDAR-dependent signaling. APOE genotype-specific effects on this pathway were dissected using EFAD-transgenic (Tg) mice (5xFAD mice, that over-express human amyloid-beta (Aβ) via 5 familial-AD (FAD) mutations, and express human apoE), and 5xFAD/APOE-knockout (KO) mice. Previous data from EFAD-Tg mice demonstrate age-dependent (2-6 months), apoE-specific effects on the development of Aβ pathology. This study tests the hypothesis that apoE4 impairs cognition via modulation of NMDAR-dependent signaling, specifically via a loss of function by comparison of E4FAD mice with 5xFAD/APOE-KO mice, E3FAD and E2FAD mice.ResultsUsing female E2FAD, E3FAD, E4FAD and 5xFAD/APOE-KO mice aged 2-, 4-, and 6-months, the Y-maze and Morris water maze behavioral tests were combined with synaptic protein levels as markers of synaptic viability. The results demonstrate a greater age-induced deficit in cognition and reduction in PSD95, drebrin and NMDAR subunits in the E4FAD and 5xFAD/APOE-KO mice compared with E2FAD and E3FAD mice, consistent with an apoE4 loss of function. Interestingly, for NMDAR-mediated signaling, the levels of p-CaMK-II followed this same apoE-specific pattern as cognition, while the levels of p-CREB and BDNF demonstrate an apoE4 toxic gain of function: E2FAD > E3FAD > 5xFAD/APOE-KO > E4FAD.ConclusionThese findings suggest that compared with E2FAD and E3FAD, E4FAD and 5xFAD/APOE-KO mice exhibit enhanced age-induced reductions in cognition and key synaptic proteins via down-regulation of an NMDAR signaling pathway, consistent with an apoE4 loss of function. However, levels of p-CREB and BDNF, signaling factors common to multiple pathways, suggest a gain of toxic function. Publications in this field present contradictory results as to whether APOE4 imparts a loss or gain of function. As with the results reported herein, the overall effect of APOE4 on a given CNS-specific measure will be the product of multiple overlapping mechanisms. Thus, caution remains critical in determining whether APOE gene inactivation or therapies that correct the loss of positive function related to apoE4, are the appropriate therapeutic response.

A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction with N-terminal Amyloid Precursor Protein, Reduces Β-Amyloid-associated Pathology, and Improves Cognition

Targeting of Nonlipidated, Aggregated Apoe with Antibodies Inhibits Amyloid Accumulation

ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Role of Apolipoprotein E in Alzheimer's Disease Pathogenesis, Prognosis and Treatment

APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

P4-402 Alzheimer's Disease Drug Discovery Targeted to the APP MRNA 5′ Untranslated Region, a Validated Target

Cell-autonomous Effects of APOE4 in Restricting Microglial Response in Brain Homeostasis and Alzheimer’s Disease

Apolipoprotein E Lipoprotein Particles Inhibit Amyloid-Β Uptake Through Cell Surface Heparan Sulphate Proteoglycan.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice

Apolipoprotein D Modulates Amyloid Pathology in APP/PS1 Alzheimer's Disease Mice

Drugs targeting APOE4 that regulate beta‐amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease

Effects of human apolipoprotein E isoforms on the amyloid β‐protein concentration and lipid composition in brain low‐density membrane domains

Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease

APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

ApoE4: an emerging therapeutic target for Alzheimer’s disease